AI-extracted from the 10-Q filed 2026-08-10 — Q2 2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Revenue was essentially flat at $112.0B, but the medical care ratio fell 2.7 points to 86.7%, lifting earnings from operations 55% to $8.0B and diluted EPS to $6.04.
Biggest Revenue Drivers
UnitedHealthcare$86.0B0% YoY
Contraction in Medicare Advantage, risk-based commercial and Medicaid members, offset by pricing trends and fee-based growth
Optum Rx$38.3B0% YoY
Reduced script volume from contraction in people served at UnitedHealthcare, partially offset by retail and specialty pharmacy growth
Biggest Revenue Drivers
Total revenue: $112.0B0% YoY
UnitedHealthcare$86.0B0% YoY
Contraction in Medicare Advantage, risk-based commercial and Medicaid members, offset by pricing trends and fee-based growth
Reduced script volume from contraction in people served at UnitedHealthcare, partially offset by retail and specialty pharmacy growth
Largest Expense Items
Medical costs$75.4B-4% YoY
Fewer people served and favorable prior period reserve development, partly offset by elevated medical cost trend
Operating costs$14.3B+4% YoY
Investments in people, process and technology, and business mix
Cost of products sold$13.4B+3% YoY
Depreciation and amortization$1.0B-4% YoY
Margins: Medical care ratio fell to 86.7% from 89.4% on favorable prior period development, affordability initiatives and pricing; operating cost ratio rose 0.4 points to 12.7%, with operating margin at 7.1%.
Watch Items from the Filing
IRS Notices of Proposed Adjustment received March 6, 2026 on 2017-2020 intercompany transfer pricing; company intends to contest and may face similar adjustments after 2020.
DOJ False Claims Act case on Medicare risk adjustment remains unresolved; a Special Master recommended summary judgment for the company, which DOJ moved to reject.
Company pledged to rebate 2026 profits on individual exchange products, and Medicare Advantage 2027 rate notice remains below forward medical cost trend.
South American businesses held for sale carry a $1,656M remeasurement to fair value less cost to sell, including $893M of cumulative foreign currency translation losses.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Noel Timothy JohnChief Executive Officer, UHCGrant or award · Sep 22, 2026
Congress trading in UNH
139 transactions in UNH reported by 40 members of Congress under the STOCK Act, most recent trade Sep 24, 2026. Reported transactions, not recommendations.
About UNITEDHEALTH GROUP INC (UNH): stock profile, AI score and financials
UNITEDHEALTH GROUP INC (UNH) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores UNH at 62.6/100 on a composite quality score built from its SEC filings, placing it at rank #683 of 2,925 stocks — the top 25% of the AI-ranked universe. UNH scores in the top quartile across revenue scale (99.8), earnings quality (82.5). Areas of concern include profitability (37.7), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), UNITEDHEALTH GROUP INC reports quarterly revenue of $112.0B, net income of $5.5B, an operating margin of 7.1%. Top institutional holders of UNH by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. UNH trades on the NYSE exchange and files with the SEC under CIK 731766. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate UNH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for UNITEDHEALTH GROUP INC directly from SEC EDGAR.